TherapeuticsMD (TXMD) Short term Debt (2013 - 2022)
TherapeuticsMD (TXMD) reported Short term Debt of $93.6 million for Q3 2022, up 524.01% on a YoY basis from $15.0 million in Q3 2021, and up 3.11% quarter-over-quarter from $90.8 million in Q2 2022.
TherapeuticsMD (TXMD) Short term Debt (2013 - 2022) Analysis & Trends
TherapeuticsMD has reported Short term Debt for 3 years, with the latest figure at $93.6 million in Q3 2022.
- For the quarter ending Q3 2022, Short term Debt rose 524.01% year-over-year to $93.6 million; the trailing twelve-month figure through Sep 2022 stood at $93.6 million (up 524.01% YoY), and the FY2021 full-year result was $188.3 million, changed N/A from the prior year.
- Short term Debt for Q3 2022 stood at $93.6 million, up from $90.8 million in the prior quarter.
- The five-year high for Short term Debt was $202.9 million in Q1 2022, with the low at $5.0 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | TherapeuticsMD | 21,180.42 | -8.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 93.60 Mn |
| Jun 30, 2022 | 90.78 Mn |
| Mar 31, 2022 | 202.86 Mn |
| Dec 31, 2021 | 188.27 Mn |
| Sep 30, 2021 | 15.00 Mn |
| Jun 30, 2021 | 10.00 Mn |
| Mar 31, 2021 | 5.00 Mn |
| Mar 31, 2013 | 100,000.00 |